Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00043940 | Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning) | PHASE3 | COMPLETED | 50 | — | — | Apr 1, 1999 | - | Sep 16, 2011 | 1 | United States |
composite incidence of major bleeding events during administration or within 48 hours after stopping bivalirudin
| Name | Type | Description |
|---|---|---|
| bivalirudin | DRUG | Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours. |
INCLUSION: * Males and females at least 18 years of age, * Be able to provide written informed consent, * Need anticoagulation for percutaneous coronary intervention (angioplasty, rotational atherectomy, directional coronary atherectomy, transluminal extraction catheter, or coronary stent), * New d...